GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID.

GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms. GeNeuro acknowledges data published in the Lancet’s EBioMedicine showing that HERV-W ENV expression was detected in the lymphocytes of all 30 studied hospitalized COVID-19 patients, versus none in healthy subjects, and that the level of HERV-W ENV was correlated with the severity of the evolution of the disease. Temelimab is an anti-HERV-W ENV monoclonal antibody, with demonstrated excellent tolerability and safety in over 400 patient-years of treatment, and is immediately available to study the effects of neutralizing HERV-W ENV in COVID-19 patients.. The discovery of HERV-W ENV circulating in the blood of COVID-19 patients potentially opens a new dimension to the disease and efforts to develop treatments to neutralize the pathogenic effects of HERVs.. See- RESEARCH PAPER|ONLINE FIRST, 103341; "Evidence of the pathogenic HERV-W envelope expression in T lymphocytes in association with the respiratory outcome of COVID-19 patients";Emanuela Balestrieri . Antonella Minutolo Vita Petrone, Marialaura Fanelli, et al., Open Access. Published:April 15,2021DOI:https://doi.org/10.1016/j.ebiom.2021.103341.